Blood is checked to assess IgA (VCA-p18 + EBNA1), viral Load, IL-8 and IL-10 in the case of NPC before and after therapy are included in the remaining 39 inclusion criteria and 29 controls. This evidence concerns the gene CXCL8 and nasopharyngeal carcinoma.